Stephen Joza,Michele T. Hu,Ki-Young Jung,Dieter Kunz,Ambra Stefani,Petr Dusek,Michele Terzaghi,Dario Arnaldi,Aleksandar Videnovic,Mya C. Schiess,Wiebke Hermann,Jee-Young Lee,Luigi Ferini-Strambi,Simon J. G. Lewis,Laurene Leclair-Visonneau,Wolfgang H. Oertel,Elena Antelmi,Friederike Sixel-Doering,Valerie Cochen De Cock,Claudio Liguori,Jun Liu,Federica Provini,Monica Puligheddu,Alessandra Nicoletti,Claudio L. A. Bassetti,Jitka Buskova,Yves Dauvilliers,Raffaele Ferri,Jacques Y. Montplaisir,Michael Lawton,Han-Joon Kim,Frederik Bes,Birgit Hoegl,Karel Sonka,Giuseppe Fiamingo,Pietro Mattioli,Maria Lorena Lavadia,Jessika Suescun,Kyung Ah Woo,Sara Marelli,Kaylena Ehgoetz Martens,Annette Janzen,Giuseppe Plazzi,Brit Mollenhauer,Mariana Fernandes,Yuanyuan Li,Pietro Cortelli,Michela Figorilli,Calogero Edoardo Cicero,Carolin Schaefer,Lily Guiraud,Giuseppe Lanza,Jean-Francois Gagnon,Jun-Sang Sunwoo,Abubaker Ibrahim,Nicola Girtler,Claudia Trenkwalder,Luca Baldelli,Amelie Pelletier,Ronald B. Postuma

Abstract:The neurodegenerative synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are characterized by a typically lengthy prodromal period of progressive subclinical motor and non-motor manifestations. Among these, idiopathic REM sleep behaviour disorder is a powerful early predictor of eventual phenoconversion, and therefore represents a critical opportunity to intervene with neuroprotective therapy. To inform the design of randomized trials, it is essential to study the natural progression of clinical markers during the prodromal stages of disease in order to establish optimal clinical end points. In this study, we combined prospective follow-up data from 28 centres of the International REM Sleep Behavior Disorder Study Group representing 12 countries. Polysomnogram-confirmed REM sleep behaviour disorder subjects were assessed for prodromal Parkinson's disease using the Movement Disorder Society criteria and underwent periodic structured sleep, motor, cognitive, autonomic and olfactory testing. We used linear mixed-effect modelling to estimate annual rates of clinical marker progression stratified by disease subtype, including prodromal Parkinson's disease and prodromal dementia with Lewy bodies. In addition, we calculated sample size requirements to demonstrate slowing of progression under different anticipated treatment effects. Overall, 1160 subjects were followed over an average of 3.3 ± 2.2 years. Among clinical variables assessed continuously, motor variables tended to progress faster and required the lowest sample sizes, ranging from 151 to 560 per group (at 50% drug efficacy and 2-year follow-up). By contrast, cognitive, olfactory and autonomic variables showed modest progression with higher variability, resulting in high sample sizes. The most efficient design was a time-to-event analysis using combined milestones of motor and cognitive decline, estimating 117 per group at 50% drug efficacy and 2-year trial duration. Finally, while phenoconverters showed overall greater progression than non-converters in motor, olfactory, cognitive and certain autonomic markers, the only robust difference in progression between Parkinson's disease and dementia with Lewy bodies phenoconverters was in cognitive testing. This large multicentre study demonstrates the evolution of motor and non-motor manifestations in prodromal synucleinopathy. These findings provide optimized clinical end points and sample size estimates to inform future neuroprotective trials.

Frequency and clinical features of Lewy body dementia in Italian memory clinics

FC20: Prevalence, Incidence, and Clinical Features of Lewy Body Dementia in the South Eastern of Spain

Clinical features of dementia with lewy bodies in 35 Chinese patients

Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology

Clinical Characteristics of Lewy Body Dementia in Chinese Memory Clinics

Clinical analysis of dementia with lewy body

Investigation of the genetic aetiology of Lewy body diseases with and without dementia

Clinical And Neuroimaging Characteristics Of Chinese Dementia With Lewy Bodies

Neuroretinal and microvascular retinal features in dementia with Lewy body assessed by optical coherence tomography angiography

Non-Pharmacological Treatments in Lewy Body Disease: A Systematic Review

Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies

Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design

Impact of Lewy bodies disease on visual skills and memory abilities: from prodromal stages to dementia

Metabolic patterns across core features in dementia with lewy bodies

Peripheral immune profile in drug-naïve dementia with Lewy bodies

Progression of Clinical Markers in Prodromal Parkinson's Disease and Dementia with Lewy Bodies: a Multicentre Study.

Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease

[Psychiatric symptoms of Lewy body dementia]

Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers

The Presence and Co-Incidence of Geriatric Syndromes in Older Patients with Mild-Moderate Lewy Body Dementia

18F-Fluorodeoxyglucose Positron Emission Tomography in Dementia with Lewy Bodies.